CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris - Alexion Pharma Canada Corp.) indication : the treatment of neuromyelitis optica spectrum disorder (NMOSD)
Eculizumab has a Health Canada indication for the treatment of NMOSD in adult patients who are anti-AQP4 antibody positive. Eculizumab is not intended for acute treatment of an NMOSD relapse. Eculizumab is a monoclonal antibody. It is available as a 30mL parenteral solution (10 mg/mL) for IV injecti...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 24, 2020, 2020
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Eculizumab has a Health Canada indication for the treatment of NMOSD in adult patients who are anti-AQP4 antibody positive. Eculizumab is not intended for acute treatment of an NMOSD relapse. Eculizumab is a monoclonal antibody. It is available as a 30mL parenteral solution (10 mg/mL) for IV injection and the Health Canada-approved dose is 900 mg weekly for the first 4 weeks, followed by 1,200 mg for the fifth dose 1 week later, then 1,200 mg every two weeks thereafter |
|---|---|
| Physical Description: | 1 PDF file (9 pages) |